药物涂层球囊与药物洗脱支架治疗支架内再狭窄的10年结局:ISAR-DESIRE 3试验
ISAR-DESIRE 3试验将402例药物洗脱支架内再狭窄患者随机分配至普通球囊、紫杉醇涂层球囊或紫杉醇洗脱支架,随访延长至10年。10年时PCB与PES的主要复合终点无显著差异,但PES在5年内死亡和心源性死亡事件增多;PES和PCB均显著降低靶病变血运重建率。
要点
- 10年时PCB与PES的主要复合终点无显著差异。
- PES在5年内死亡和心源性死亡事件较PCB增多,但10年差异未达统计学显著。
- PES和PCB均显著降低靶病变血运重建率。
核心结论
- DES-ISR患者PCI后10年,PCB与PES的主要和主要次要终点无显著差异。
- PES与5年内死亡和心源性死亡事件增多相关,但需进一步分析解读。
- PES和PCB较PB显著降低靶病变血运重建率。
研究设计与样本
- ISAR-DESIRE 3试验将402例DES-ISR患者(500处病变)随机分配至PB(134例,160处病变)、PCB(137例,172处病变)或PES(131例,168处病变)。
- 临床随访延长至10年,事件由独立裁决。
- 主要终点为心源性死亡、靶血管心肌梗死、靶病变血栓或靶病变血运重建的复合终点。
主要发现
- 10年主要复合终点发生率:PB组72.0%(90例),PCB组55.9%(70例),PES组62.4%(72例),P<0.001。
- PCB与PES比较:主要复合终点多因素校正后P=0.610;加权Cox HR 1.10(95%CI 0.80-1.51);Cox HR 1.10(95%CI 0.79-1.52);Royston-Parmar HR 1.08(95%CI 0.72-1.60)。
- 主要次要安全终点发生率:PB组34.1%(39例),PCB组34.0%(39例),PES组40.0%(42例),P=0.564。
- 靶病变血运重建发生率:PB组58.0%(71例),PCB组43.9%(55例),PES组38.6%(42例),P<0.0001;PES与PCB比较多因素校正后P=0.282。
- 5年内PES较PCB死亡和心源性死亡事件增多,10年差异经多重性校正后未达统计学显著。
关键数值与推荐
- 主要复合终点:心源性死亡、靶血管心肌梗死、靶病变血栓或靶病变血运重建。
- 主要次要安全终点:心源性死亡、靶血管心肌梗死或靶病变血栓。
- 主要次要疗效终点:靶病变血运重建。
临床怎么用
- 对于DES-ISR患者,PCB和PES均可显著降低靶病变血运重建风险,优于普通球囊。
- PCB与PES在10年主要复合终点上无显著差异,但PES与5年内死亡风险增加相关,选择时需个体化权衡。
局限性
- PES与5年内死亡和心源性死亡事件增多的结果及竞争风险分析需进一步解读。
- 10年死亡差异经多重性校正后未达统计学显著。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: The best interventional strategy for the treatment of drug-eluting stent (DES) in-stent restenosis (ISR) is still unclear and no data from randomized trials beyond 3-year follow-up are available. We aimed to define 10-year comparative efficacy and safety of plain balloon (PB), paclitaxel-coated balloon (PCB), and paclitaxel-eluting stent (PES) for percutaneous coronary intervention (PCI) of DES-ISR. METHODS AND RESULTS: Clinical follow-up of patients randomly assigned to PB, PCB, and PES in the ISAR-DESIRE 3 trial was extended to 10 years and events were independently adjudicated. The primary endpoint was a composite of cardiac death, target vessel myocardial infarction, target lesion thrombosis, or target lesion revascularization. The major secondary safety endpoint was a composite of cardiac death, target vessel myocardial infarction, or target lesion thrombosis. The major secondary efficacy endpoint was target lesion revascularization. Incidences by the Kaplan-Meier method were compared by the log-rank test. Risk estimation was primarily performed by Cox proportional hazards regression and supplemented by weighted Cox regression accounting for non-proportional hazards and Royston-Parmar flexible parametric regression with a time-varying coefficient. Primary results were further assessed by landmark, lesion-level, per-protocol, and competing risk analyses. A total of 402 patients (500 lesions) with DES-ISR were randomly assigned to PB angioplasty (134 patients, 160 lesions), PCB angioplasty (137 patients, 172 lesions), and PES implantation (131 patients, 168 lesions). Clinical follow-up did not significantly differ among treatments [PB, 9.62 (4.50-10.02) years; PCB, 10.01 (5.72-10.02) years; PES, 9.08 (3.14-10.02) years; P = 0.300]. At 10 years, the primary composite endpoint occurred in 90 patients (72.0%) assigned to PB, 70 patients (55.9%) assigned to PCB, and 72 patients (62.4%) assigned to PES (P < 0.001). The pairwise comparison between PCB and PES resulted in a non-significant difference [multiplicity-adjusted P = 0.610; Grambsch-Therneau P = 0.004; weighted Cox: hazard ratio (HR) 1.10, 95% confidence interval (CI) 0.80-1.51; Cox: HR 1.10, 95% CI 0.79-1.52; Royston-Parmar: HR 1.08, 95% CI 0.72-1.60]. The major secondary safety endpoint occurred in 39 patients (34.1%) assigned to PB, 39 patients (34.0%) assigned to PCB, and 42 patients (40.0%) assigned to PES (P = 0.564). Target lesion revascularization occurred in 71 patients (58.0%) assigned to PB, 55 patients (43.9%) assigned to PCB, and 42 patients (38.6%) assigned to PES (P < 0.0001). The pairwise comparison between PES and PCB resulted in a non-significant difference (multiplicity-adjusted P = 0.282; Grambsch-Therneau P = 0.002; weighted Cox: HR 0.83, 95% CI 0.56-1.22; Cox: HR 0.81, 95% CI 0.54-1.21; Royston-Parmar: HR 0.75, 95% CI 0.47-1.20). Lesion-level and per-protocol analyses were consistent. At landmark analyses, an excess of death and cardiac death associated with PES compared with PCB was observed within 5 years after PCI, though 10-year differences did not formally reach the threshold of statistical significance after adjustment for multiplicity. Competing risk regression confirmed a non-significant difference in target lesion revascularization between PCB and PES and showed an increased risk of death associated with PES compared with PCB. CONCLUSION: Ten years after PCI for DES-ISR, the primary and major secondary endpoints between PCB and PES were not significantly different. However, an excess of death and cardiac death within 5 years associated with PES and the results of the competing risk analysis are challenging to interpret and warrant further analysis. PES and PCB significantly reduced target lesion revascularization compared with PB.
引用
- Giacoppo D, Alvarez-Covarrubias HA, Koch T, et al. Coronary artery restenosis treatment with plain balloon, drug-coated balloon, or drug-eluting stent: 10-year outcomes of the ISAR-DESIRE 3 trial. Eur Heart J. 2023. PMID: 36807512. doi:10.1093/eurheartj/ehad026
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。